Ranibizumab Treatment for Age-Related Macular Degeneretion

Inclusion Criteria: * Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD * Subjects of either gender age 50 years or older * Visual acuity better than 0.05 decimal( 20/400 Snellen) * Signed informed consent form Exclusion Criteria: * Prior treatment for neovascular AMD in the study eye, for example, PDT or anti-VEGF therapy * Patients whose lesion site evaluated by FA examination is more than 12DA in subject eye * Patients with treatment of triamcinolone intravitreal injection within 6 months in subject eye * Patients with a history of intraocular surgical operation(including cataract)within 3 months in subject eye * Patients with serious allergic history to such as fluorescein, indocyanine green, iodophors * The pregnant or lactating woman